Literature DB >> 33750303

Anesthetics may modulate cancer surgical outcome: a possible role of miRNAs regulation.

Masashi Ishikawa1,2, Masae Iwasaki3,4, Atsuhiro Sakamoto3, Daqing Ma4.   

Abstract

BACKGROUND: microRNAs (miRNAs) are single-stranded and noncoding RNA molecules that control post-transcriptional gene regulation. miRNAs can be tumor suppressors or oncogenes through various mechanism including cancer cell biology, cell-to-cell communication, and anti-cancer immunity. MAIN BODY: Anesthetics can affect cell biology through miRNA-mediated regulation of messenger RNA (mRNA). Indeed, sevoflurane was reported to upregulate miR-203 and suppresses breast cancer cell proliferation. Propofol reduces matrix metalloproteinase expression through its impact on miRNAs, leading to anti-cancer microenvironmental changes. Propofol also modifies miRNA expression profile in circulating extracellular vesicles with their subsequent anti-cancer effects via modulating cell-to-cell communication.
CONCLUSION: Inhalational and intravenous anesthetics can alter cancer cell biology through various cellular signaling pathways induced by miRNAs' modification. However, this area of research is insufficient and further study is needed to figure out optimal anesthesia regimens for cancer patients.

Entities:  

Keywords:  Anesthetics; Anti-cancer immunity; Cancer; Cell-to-cell communication; MicroRNA

Mesh:

Substances:

Year:  2021        PMID: 33750303      PMCID: PMC7941705          DOI: 10.1186/s12871-021-01294-w

Source DB:  PubMed          Journal:  BMC Anesthesiol        ISSN: 1471-2253            Impact factor:   2.217


  177 in total

1.  Combinatorial microRNA target predictions.

Authors:  Azra Krek; Dominic Grün; Matthew N Poy; Rachel Wolf; Lauren Rosenberg; Eric J Epstein; Philip MacMenamin; Isabelle da Piedade; Kristin C Gunsalus; Markus Stoffel; Nikolaus Rajewsky
Journal:  Nat Genet       Date:  2005-04-03       Impact factor: 38.330

2.  Prognostic role of microRNA polymorphisms in patients with advanced esophageal squamous cell carcinoma receiving platinum-based chemotherapy.

Authors:  Chaohui Wu; Minjie Li; Chao Hu; Hongbing Duan
Journal:  Cancer Chemother Pharmacol       Date:  2013-11-28       Impact factor: 3.333

3.  MicroRNA-455-3p functions as a tumor suppressor by targeting eIF4E in prostate cancer.

Authors:  Yongxiang Zhao; Mingyu Yan; Ye Yun; Jianguo Zhang; Ruimin Zhang; Yan Li; Xiangming Wu; Qiang Liu; Wei Miao; Haishan Jiang
Journal:  Oncol Rep       Date:  2017-03-13       Impact factor: 3.906

Review 4.  Targeting HIF-1 for cancer therapy.

Authors:  Gregg L Semenza
Journal:  Nat Rev Cancer       Date:  2003-10       Impact factor: 60.716

5.  Propofol suppresses proliferation and invasion of glioma cells by upregulating microRNA-218 expression.

Authors:  Jinquan Xu; Weiyun Xu; Jiaqun Zhu
Journal:  Mol Med Rep       Date:  2015-07-01       Impact factor: 2.952

6.  Isoflurane promotes glucose metabolism through up-regulation of miR-21 and suppresses mitochondrial oxidative phosphorylation in ovarian cancer cells.

Authors:  Nai-Liang Guo; Jia-Xin Zhang; Jing-Ping Wu; Ying-Hua Xu
Journal:  Biosci Rep       Date:  2017-12-12       Impact factor: 3.840

7.  MicroRNA-455-3p promotes invasion and migration in triple negative breast cancer by targeting tumor suppressor EI24.

Authors:  Zhishuang Li; Qingyong Meng; Aifeng Pan; Xiaojuan Wu; Jingjing Cui; Yan Wang; Li Li
Journal:  Oncotarget       Date:  2017-03-21

8.  Propofol attenuates sepsis-induced acute kidney injury by regulating miR-290-5p/CCL-2 signaling pathway.

Authors:  Guodong Zheng; Hong Qu; Fen Li; Weiquan Ma; Hong Yang
Journal:  Braz J Med Biol Res       Date:  2018-10-11       Impact factor: 2.590

9.  In vivo activity of miR-34a mimics delivered by stable nucleic acid lipid particles (SNALPs) against multiple myeloma.

Authors:  Maria Teresa Di Martino; Virginia Campani; Gabriella Misso; Maria Eugenia Gallo Cantafio; Annamaria Gullà; Umberto Foresta; Pietro Hiram Guzzi; Maria Castellano; Anna Grimaldi; Vincenzo Gigantino; Renato Franco; Sara Lusa; Mario Cannataro; Pierosandro Tagliaferri; Giuseppe De Rosa; Pierfrancesco Tassone; Michele Caraglia
Journal:  PLoS One       Date:  2014-02-27       Impact factor: 3.240

10.  Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours.

Authors:  David S Hong; Yoon-Koo Kang; Mitesh Borad; Jasgit Sachdev; Samuel Ejadi; Ho Yeong Lim; Andrew J Brenner; Keunchil Park; Jae-Lyun Lee; Tae-You Kim; Sangjoon Shin; Carlos R Becerra; Gerald Falchook; Jay Stoudemire; Desiree Martin; Kevin Kelnar; Heidi Peltier; Vinicius Bonato; Andreas G Bader; Susan Smith; Sinil Kim; Vincent O'Neill; Muhammad S Beg
Journal:  Br J Cancer       Date:  2020-04-02       Impact factor: 7.640

View more
  3 in total

Review 1.  Effects of Propofol Versus Sevoflurane on Postoperative Breast Cancer Prognosis: A Narrative Review.

Authors:  Panpan Fang; Jiaqi Zhou; Zhengyuan Xia; Yao Lu; Xuesheng Liu
Journal:  Front Oncol       Date:  2022-01-20       Impact factor: 6.244

2.  Propofol Inhibits Proliferation and Augments the Anti-Tumor Effect of Doxorubicin and Paclitaxel Partly Through Promoting Ferroptosis in Triple-Negative Breast Cancer Cells.

Authors:  Chen Sun; Pan Liu; Lijian Pei; Mengyun Zhao; Yuguang Huang
Journal:  Front Oncol       Date:  2022-03-28       Impact factor: 6.244

Review 3.  Anesthetics and Long Term Cancer Outcomes: May Epigenetics Be the Key for Pancreatic Cancer?

Authors:  Zhirajr Mokini; Alessandro Cama; Patrice Forget
Journal:  Medicina (Kaunas)       Date:  2022-08-14       Impact factor: 2.948

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.